Table 3.
Comparison of variations in general health (GH) and visual analog scale (VAS) pain scores between patients who were visited at least once and those who were assessed by telemedicine only
| Overall | Rheumatoid arthritis | Psoriatic arthritis | Ankylosing spondylitis | |||||
|---|---|---|---|---|---|---|---|---|
| N = 341 | N = 197 | N = 85 | N = 59 | |||||
| Univariate (95% CI) | Multivariate* (95% CI) | Univariate (95% CI) | Multivariate* (95% CI) | Univariate (95% CI) | Multivariate* (95% CI) | Univariate (95% CI) | Multivariate* (95% CI) | |
| GH, score 0–100, Δ T1-T0 | ||||||||
| Age, 1-year unit | 0.04 (− 0.09, 0.17) | − | 0.13 (− 0.05, 0.31) | − | − 0.10 (− 0.36, 0.16) | − | 0.10 (− 0.23, 0.44) | − |
|
Male Female as ref |
− 1.37 (− 4.8, 2.1) | − | − 5.8 (− 11.70, 0.03) | − | 1.29 (− 4.56, 7.15) | − | 0.25 (− 7.70, 8.2) | − |
|
TNFi Other bDMARDs as ref |
3.05 (− 0.53, 6.61) | − | 3.08 (− 1.73, 7.90) | − | 3.81 (− 2.76, 10.37) | − | − 4.95 (− 18.57, 8.67) | − |
| GH at baseline | − 0.15 (− 0.21, − 0.10) | − | − 0.18 (− 0.25, − 0.10) | − | − 0.10 (− 0.22, 0.02) | − | − 0.14 (− 0.26, − 0.02) | − |
| At least 1 visit | − 1.61 (− 5.12, 1.89) | − 0.59 (− 3.97, 2.79) | − 3.70 (− 8.57, 1.17) | − 1.99 (− 6.60, 2.62) | 0.07 (− 6.08, 6.24) | 0.42 (− 5.88, 6.72) | 5.54 (− 3.08, 14.16) | 8.87 (0.57, 17.16) |
| VAS pain, score 0–100, Δ T1–T0 | ||||||||
| Age, 1-year unit | 0.10 (− 0.02, 0.23) | − | 0.20 (0.03, 0.37) | − | − 0.10 (− 0.36, 0.16) | − | 0.35 (− 0.0004, 0.70) | |
|
Male Female as ref |
− 1.03 (− 4.43, 2.37) | − | − 2.87 (− 8.50, 2.75) | − | − 0.98 (− 6.94, 4.98) | − | − 1.34 (− 9.94, 7.25) | |
|
TNFi Other bDMARDs as ref |
0.70 (− 2.83, 4.22) | − | 0.74 (− 3.87, 5.34) | − | 1.63 (− 5.09, 8.35) | − | − 10.48 (− 25.00, 4.04) | |
| GH at baseline | − 0.17 (− 0.22, − 0.11) | − | − 0.18 (− 0.26, − 0.11) | − | − 0.12 (− 0.24, 0.01) | − | − 0.17 (− 0.30, − 0.05) | |
| At least 1 visit | − 4.3 (− 7.70, − 0.85) | − 2.9 (− 6.21, 0.34) | − 3.99 (− 8.62, 0.64) | − 2.28 (− 6.61, 2.06) | − 5.87 (− 12.01, 0.27) | − 5.32 (− 11.60, 0.95) | − 1.80 (− 11.25, 7.64) | 5.54 (− 2.99, 14.07) |
CI confidence interval, GH general health, TNFi tumor necrosis factor inhibitor, VAS visual analog scale, T0 patient-reported outcome evaluation before lockdown (between 1st January 2020 and 1st March 2020), T1 patient-reported outcome evaluation after lockdown (between 1st June 2020 and 1st August 2020), Δ T1–T0 Variation between patient-reported outcomes in T1 and T0,
*Adjusted for age, gender, anti-tumor necrosis factor therapy, and baseline patient-reported outcomes